Clinical and angiographic characteristics of patients with SAP and UAP in whom MPO was quantified between angiographically-detected simple versus complex lesion groups
| SAP | UAP | |||||
| Simple (n=94) | Complex (n=52) | p Value | Simple (n=97) | Complex (n=139) | p Value | |
| Age (years) | 65±9 | 65±10 | 0.95 | 65±10 | 66±10 | 0.30 |
| Male (%) | 77 | 81 | 0.56 | 75 | 71 | 0.42 |
| Hypertension (%) | 68 | 62 | 0.64 | 72 | 66 | 0.33 |
| Hypercholesterolaemia (%) | 54 | 50 | 0.62 | 51 | 58 | 0.29 |
| Diabetes mellitus (%) | 40 | 37 | 0.64 | 32 | 40 | 0.23 |
| Smoking (%) | 64 | 52 | 0.16 | 53 | 50 | 0.66 |
| Braunwald class III (%) | – | – | – | 45 | 62 | 0.01 |
| Total cholesterol (mg/dl) | 194±32 | 184±28 | 0.06 | 201±34 | 201±40 | 0.94 |
| HDL cholesterol (mg/dl) | 49±13 | 45±11 | 0.06 | 48±11 | 46±11 | 0.10 |
| LDL cholesterol (mg/dl) | 113±31 | 103±28 | 0.06 | 119±35 | 126±42 | 0.22 |
| Triglycerides (mg/dl) | 156±94 | 178±128 | 0.24 | 152±90 | 143±82 | 0.46 |
| Elevated TnT >0.1 ng/ml (%) | – | – | – | 20 | 26 | 0.26 |
| Medications at hospital admission | ||||||
| Aspirin (%) | 59 | 67 | 0.30 | 100 | 100 | – |
| Beta-blockers (%) | 16 | 29 | 0.06 | 25 | 30 | 0.39 |
| Calcium antagonists (%) | 56 | 48 | 0.34 | 59 | 53 | 0.34 |
| Nitrates (%) | 33 | 40 | 0.37 | 31 | 29 | 0.77 |
| ACE inhibitors/ARB (%) | 18 | 31 | 0.08 | 48 | 43 | 0.37 |
| Lipid-lowering agents (%) | 28 | 37 | 0.27 | 34 | 35 | 0.87 |
| QCA analysis | ||||||
| Reference diameter (mm) | 3.0 (2.6–3.4) | 2.7 (2.4–3.1) | 0.04 | 3.2 (2.9–3.5) | 3.1 (2.7–3.5) | 0.04 |
| MLD (mm) | 0.64 (0.43–0.79) | 0.28 (0.02–0.53) | <0.001 | 0.48 (0.07–0.72) | 0.30 (0–0.59) | 0.04 |
| DS (%) | 78 (75–86) | 91 (83–99) | <0.001 | 60 (54–65) | 88 (81–99) | 0.02 |
| Multiple complex plaque (%) | – | 19 | – | – | 29 | – |
| LVEF (%) | 59±11 | 58±10 | 0.84 | 59±9 | 57±9 | 0.13 |
| Leucocyte count (/mm3) | (5103–7308) | 6315 (5138–7388) | 0.77 | 6600 (5510–7950) | 6550 (5543–8175) | 0.47 |
| Neutrophil count (/mm3) | 3472 (2721–4461) | 3480 (2775–4448) | 0.90 | 3793 (3090–5112) | 4118 (3256–5163) | 0.16 |
| hs-CRP (mg/dl) | 0.11 (0.05–0.22) | 0.09 (0.05–0.19) | 0.55 | 0.13 (0.06–0.31) | 0.14 (0.05–0.34) | 0.86 |
| MPO (ng/ml) | 18.2 (14.8–24.7) | 19.3 (16.3–24.0) | 0.43 | 20.5 (15.9–27.9) | 41.9 (21.7–73.8) | <0.0001 |
Categorical variables are expressed as percentages and continuous variables as mean±SD or median (interquartile ranges) as appropriate.
ACE, angiotensin converting enzyme; ARB, angiotensin II type 1 receptor blockers; DS, diameter stenosis; HDL, high density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low density lipoprotein; LVEF, left ventricular ejection fraction; MLD, minimal lumen diameter; MPO, myeloperoxidase; QCA, quantitative coronary angiography; SAP, stable angina pectoris; TnT, troponin T; UAP, unstable angina pectoris.